Astrazeneca Ab

Nps Allelix Corporation

Nps Pharmaceuticals, Inc.

Apotex Inc.

Allelix Biopharmaceuticals Inc.

Apotex Technologies Inc.

Pharmala Biotech Inc.

Nps Allelix Biopharmaceuticals, Inc.

Tao Xin

Abdelmalik Slassi

Louise G Edwards

Methvin Benjamin Isaac

Ashok Tehim

Jalaj Arora

Tomislav Stefanac

David Wensbo

Anne O'Brien

Tim Fat Tam

Regis C Leung-Toung

Donald A McLeod

Alexander Minidis

Yanqing Zhao

Yingsheng Wang

Birenkumar Hasmukhbhai Shah

Martin Johansson

Annika Kers

Ian Egle

Shawn Maddaford

Thomas M Stormann

Blaise N'Zemba

Jolanta Maria Wodzinska

Karin Staaf

Maryna Premyslova

Methvin Issac

Scott T Moe

Khashayar Karimian

Daryl Lynn Smith

Kenneth Lars Granberg

Peter Dove

Andreas Christer Wallberg

Susan M Sheehan

Guy A Higgins

Ulrika Yngve

Erwan Arzel

Qi Qiao

Bo Lei

Helena Gyback

Karolina Nilsson

Mats Nagard

Johan Malmberg

Tom Stefanac

Don McLeod

Caroline Eriksson

Veronica Profir

Per-Olov Bergstrom

John Malmberg

Karin Oscarsson

Mangus Waldman

Christoffer Osterwall

William Michne

Harpreet Kaur

Bradford Van Wagenen

Björn Holm

Methvin Nps Allelix Corp Isaac

Donald Nps Pharmaceuticals Inc Mcleod

Donald Mcleod

Thomas Stormann

Marina Premyslova

Blaise N'zemba

Louise Nps Allelix Corp Edwards

Abdelmalik Nps Allelix Corp Slassi

Alexander Astrazeneca R & D Headquarters Minidis

Martin Astrazeneca R & D Headquarters Johansson

David Astrazeneca R & D Headquarters Wensbo

Anne Nps Allelix Corp O'BRIEN

Karin Astrazeneca R & D Headquarters Staaf

The present application includes an enantiomerically pure compound of Formula (R)-I or a salt and/or solvate thereof. Also included are compositions of the enantiomerically pure compound of Formula (R)-I as well as methods of using the compound of Formula (R)-I or composition thereof for treating, for example, disease, disorder or condition that benefits from psychotherapy. The present application also includes a composition comprising a non-racemic mixture a compound of Formula (R)-I, or a salt and/or solvate thereof, and (S)-I, or a salt and/or solvate thereof: wherein (R)-I, or a salt and/or solvate thereof, is present in the composition in a greater amount by enantiomeric equivalents, relative to (S)-I, or a salt and/or solvate thereof and uses thereof. Further included are process preparing a compound of Formula (R)-I or (S)-I.

(R)-2-[(2H-1,3-benzodioxol-5-yl)methyl]pyrrolidine and processes for preparation, compositions and uses thereof

Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.

Fluorinated derivatives of 3-hydroxypyridin-4-ones

Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Frederich's Ataxia.

Fluorinated derivates of 3-hydroxypyridin-4-ones

Described herein are compounds with affinity for the 5-HTreceptor, which have the general formula I: 

Azaindoles having serotonin receptor affinity

Compounds of formula (I) wherein Ris as well as pharmaceutically acceptable salts, hydrates and/or enantiomers thereof are useful as compounds that exhibit activity at metabotropic glutamate receptors.

Pharmaceutically active compounds containing tetrazolyl and triazolyl rings

Compounds of Formula I are useful in the treatment of epilepsy, neuropathic pain, acute and chronic inflammatory pain, migraine, tardive dyskinesia and other related CNS disorders. wherein:

Fluorinated compounds

The present invention is directed to compounds of formula I: Wherein Rto R, X and Z are further defined in the description. The invention also relates to processes for the preparation of the compounds and to intermediates used in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

mGluR5 modulators

The present invention relates to new compounds of formula I, wherein P, Q, X, X, X, X, R, R, m and p, are as defined as in formula I, or, salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

Tetrazole compounds and their use as metabotropic glutamate receptor antagonists

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

MGluR5 modulators I

The present invention is directed to compounds of formula I: wherein X, X, X, X, X, X, X, X, X, X, R, R, R, R, and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.

Compounds for the treatment of neurological, psychiatric or pain disorders

The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing compounds of the formula I and to the use of compounds of the formula I in therapy.

Compounds

Described herein are compounds with affinity for the 5-HTreceptor, which have the general formula I: Wherein A, B, D, E, Rto Rand n are described herein. Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HTreceptor is implicated, such as schizophrenia.

The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Growing community of inventors

Toronto, Canada

Tao Xin